key: cord-0255048-w9d8nzyn
authors: Aguilar, A. G.; Beauregard, B. A.; Conroy, C. P.; Khatiwoda, Y. T.; Horsford, S. M. E.; Nichols, S. D.; Piper, B. J.
title: Pronounced Regional Variation in Esketamine and Ketamine Prescribing to US Medicaid Patients
date: 2022-04-27
journal: nan
DOI: 10.1101/2022.04.23.22274206
sha: e095653c87db7c0d898e637b1dcc87c1e5d051b1
doc_id: 255048
cord_uid: w9d8nzyn

Background: Ketamine, and its isomer esketamine are useful for treatment resistant depression (depression not responsive to traditional antidepressants). Compared to other antidepressants, ketamine and esketamine lack a therapeutic delay and do not increase risk of suicidality in adolescents. Esketamine gained FDA approval in March of 2019. Objective: This study aimed to geographically characterize ketamine and esketamine prescriptions in the United States among Medicaid patients. Methods: Ketamine and esketamine prescription rate data per state per quarter were obtained from the Medicaid State Drug Utilization Database for 2019-2020. Total prescription rates per year for ketamine and esketamine were obtained for 2009-2020. Results: Between 2009-2020, ketamine prescribing rates peaked in 2013 followed by a general decline. For ketamine and esketamine prescriptions in 2019, Montana and Indiana showed significantly higher prescription rates, respectively, relative to the national average. A total of 21 states prescribed neither ketamine or esketamine in 2019. Since its approval, esketamine prescriptions have surpassed those of ketamine. There was a 121.3% increase in esketamine prescriptions from 2019 to 2020. Ten states prescribed neither ketamine or esketamine in 2020. Conclusion: Despite the effectiveness of ketamine and esketamine for treatment resistant depression, their use among Medicaid patients was limited and variable in many areas of the US.

Suicide rates continued to increase in the United States marking the presence of a suicide epidemic.

Suicide was the second leading cause of death for people aged 10-34 years old in 2019 [1] . Suicide ranks as the 10th leading cause of death with 4.8% of adults having thoughts of suicide and 0.6% (1, 969, 200) reporting having had attempted suicide in the past year [1] . Since the emergence of COVID-19, serious suicide attempts have increased in adolescent girls but not in boys [2] . The rate of serious suicide attempt ED visits increased by 50.6% in girls in 2021 compared with the same time frame in 2019 [2] . Among boys, the increase in serious suicide attempts was only 3.7% [2] . Unfortunately, traditional antidepressants are often ineffective in preventing suicide linked to depression for two reasons. First, treatment resistant depression, or failure to respond to traditional antidepressants is present in up to twothirds of patients and second, a time lag of weeks to months delays the onset of therapeutic effects [3] .

Second, traditional antidepressants have been found to counterintuitively increase the risk of suicidality in the first month of therapy in patients who are under 25. This effect was not found in adults and a protective effect was observed in geriatric adults, emphasizing age related differences in suicidality and response to medications [4] .

Ketamine, a well-known anesthetic agent, has gained attention as an antidepressant using a novel mechanism of action and is very useful for reducing suicidal ideation [5] . Its absence of therapeutic delay and effectiveness for treatment-resistant depression are well-suited for patients at risk of suicide [3] . By being effective in both major unipolar and bipolar depressive episodes, unlike other antidepressants, it is . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22274206 doi: medRxiv preprint useful for depression even when the diagnostic picture is unclear. In March of 2019, the FDA issued a conditional approval of esketamine, a stereoisomer of ketamine, as nasal spray which is administered under direct supervision of a medical provider. It is approved for use in patients with treatment resistant depression or with depression and acute suicidality. This is a landmark development as existing antidepressants have a black-box warning for young-adults for increasing suicide.

The objective of this study was to examine patterns in ketamine and esketamine prescription rates throughout the United States among Medicaid patients. Determining geographic variability in prescription could be useful for correlating use of ketamine and esketamine to rates of suicide and beginning to examine corrective efforts on a population level. Given the recency of esketamine to the market and its current high visibility in the field, these trends may be particularly useful.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22274206 doi: medRxiv preprint

Ketamine and esketamine prescription rates were obtained from the Medicaid State Drug Utilization database [6] . Medicaid is a joint federal and state program that provides coverage for 75 million people, approximately 21% of the United States population. All states provide coverage for outpatient prescription drugs [6] . We evaluated the Medicaid State Drug Utilization database for total outpatient ketamine and esketamine prescriptions per state per quarter during 2019-2020 [6] . Prescription rates were reported per 1,000,000 Medicaid enrollees. Formulations were categorized by National Drug Codes IRBs.

The following analyses were completed: 1) esketamine percent change of prescription rate from 2012 to 2013, and 2) a 95% confidence interval (mean ± 1.96*SD) with states outside this range interpreted as significantly different from the mean. We analyzed the data and constructed figures using SAS, JMP and GraphPad Prism.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22274206 doi: medRxiv preprint Pronounced geographical differences were also identified. For ketamine, Montana (967.3) showed a statistically significant (p < .05) higher rate of prescription relative to the national average ( Figure 2A ).

There was a 116-fold higher rate of prescriptions in Montana relative to the lowest state (MA = 8.3).

States in the southern US from New Mexico to South Carolina had no ketamine prescriptions (Supplemental Figure 1 ). For esketamine, Indiana (424.6) showed a significantly higher rate of prescription which was also 61-fold higher than the lowest state (Supplemental Figure 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

There are two key findings from this report. First was the increasing, but still quite low, quarterly increase in esketamine relative to ketamine. Esketamine prescriptions in 2019 were less than half (44.2%) those of ketamine in 2019, likely due to its recent FDA-approval and introduction to the market. Second, the statelevel differences in esketamine prescription rates were notable. For example, one state, Indiana prescribed 25% of the national total in 2019. At the beginning of 2019, quarterly esketamine was prescribed at a rate close to zero, but as the year progressed, a subset of states quickly adapted to use of esketamine. This was perhaps due to the large marketing budget in those states, increasing clinical evidence and wider distribution of trial results, and the rapid establishment of protocols and procedures that meet the FDA Risk Evaluation and Mitigation Strategy program requirements. The pronounced differences in esketamine prescribing at a state-level could largely be attributed to marketing rather than long-standing preset preferences in patients and physicians since this is a new drug to the market. It will likely be a fruitful endeavor to determine how use of these agents change in future years.

The identification of the rapid therapeutic and anti-suicidality effects of ketamine is potentially one of the most important developments in psychopharmacology in the past two decades. However, we found that the use of esketamine and ketamine among Medicaid patients was both modest, relative to the prevalence of depression and treatment resistant depression, and extremely variable [11] . This variability is shown by the absence of ketamine/esketamine prescriptions in two-fifths of US states in an outpatient setting. The role of ketamine in the US as an antidepressant is continues to evolve [12, 13] .

Regardless of the underlying reasons, it is interesting to note that the rates of ketamine prescribing are nowhere near as high as one might expect from an antidepressant in a class on its own which overcomes the therapeutic lag of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. Among the top two-hundred most prescribed medications known for their antidepressant . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22274206 doi: medRxiv preprint effects written for Medicaid patients in 2019 [6] , fluoxetine was the most prescribed. The ratio of fluoxetine to ketamine prescription was nearly an eight-hundred-fold difference [6] . While it is not yet conclusive that a "miracle drug" has been found to treat depression, the rates of prescribing suggest peripheral challenges like the logistics of proper administration and/or social inertia on the use of this psychoactive and controlled substance that may be causing delays. The COVID-19 pandemic likely also contributed to the limited utilization of these agents. However, there have also been fourteen ketamine/esketamine manuscripts which were subsequently retracted (e.g. use of ketamine in the ER) which may also be contributing to some ambiguity [14, Supplemental Appendix C] . There are also serious concerns with misuse, the development of tolerance [15] and tremendous costs of esketamine and monitoring relative to more traditional treatments [16] [17] [18] .

Depression leads to significant long term negative effects for both social and personal health indicators, leading to a decreased effectiveness in the workforce and for the individual's self-actualization [19] .

Suicide was the leading cause of death in 2019 among individuals who belonged to the age of group 10-35 years old. Depression prevalence has been evaluated in various studies to be as low as 5% and as high as 22.3% within the adult Medicaid population, correlating to the format of the Patient Health Questionnaire used in each individual study [11] . Nearly 58% of respondents in a 2005/06 survey on National Health and Drug use stated that there was either a gap in their major depressive disorder treatment: receiving a lack of actual treatment, or an unmet need while receiving treatment, or both [19] .

While rates of bipolar disorder are much lower than those of major depressive disorder, rates of death by suicide in this population approach 20% and are 20 -30 times that of the general population making this a key area of intervention [17] . Ketamine and esketamine may play a pivotal role in helping to bridge this care gap. Regardless, continual tracking of ketamine prescription rate helps one better understand the standard of care for depression and among treatment resistant patients at heightened risk of suicide and identify policy opportunities aimed at optimizing care in this vulnerable population.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22274206 doi: medRxiv preprint

In conclusion, this study found that low and extremely regionally disparate, rates of ketamine and esketamine prescribing to Medicaid patients in 2019 and 2020. It will likely be a fruitful endeavor to continue to monitor how use of these agents change in future years.

BJP was supported by the Health Resources Services Administration ((D34HP31025). Software used in this effort was provided by the NIEHS (T32-ES007060-31A1). Iris Johnston provided technical support.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 27, 2022. ; https://doi.org/10.1101/2022.04.23.22274206 doi: medRxiv preprint

Department of Health and Human Services. (n.d.). Suicide. National Institute of Mental Health

Emergency department visits for suspected suicide attempts among persons aged 12-25 years before and during the COVID-19 pandemic -United States

Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide

Suicide and antidepressants: What current evidence indicates

The effects of ketamine on suicidality across various formulations and study settings

State Drug Utilization Data. Medicaid. (n.d.). Retrieved

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

Ketamine for depression: Where do we go from here?

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled . CC-BY-NC-ND 4.0 International license It is made available under a add-on trial

Prevalence and medical costs of chronic diseases among adult Medicaid beneficiaries

Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation

Ketamine after two antidepressants?

New York: The Center for Scientific Integrity

Unmet need for treatment of major depression in the US

Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?

The effectiveness and value of esketamine for the management of treatment-resistant Depression: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council

Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression

Cost-effectiveness of esketamine nasal spray for patients with treatmentresistant depression in the United States